Aprea Therapeutics, Inc. (APRE) NASDAQ
0.78
-0.0359(-4.40%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.78
-0.0359(-4.40%)
Currency In USD
| Previous Close | 0.82 |
| Open | 0.8 |
| Day High | 0.8 |
| Day Low | 0.77 |
| 52-Week High | 2.22 |
| 52-Week Low | 0.55 |
| Volume | 88,686 |
| Average Volume | 370,249 |
| Market Cap | 5.07M |
| PE | -0.52 |
| EPS | -1.49 |
| Moving Average 50 Days | 0.84 |
| Moving Average 200 Days | 1.07 |
| Change | -0.04 |
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose levelPatient experienced only Grade 1 adverse events Represents second patient with PR to harbor PPP2R1A mutation, supporting mechanistic thesis of targeting WE
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while min
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
GlobeNewswire Inc.
Feb 12, 2026 1:30 PM GMT
New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea’s WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045. Lead WEE1 inhibitor candidate APR-1051 is advancing in Phase 1 trials